Year 2022 (56)
Edition nr. 12
Interchangeability of biosimilars
Over the last 15 years, a large number of so-called ‘biosimilars’ have been marketed. Biosimilars are biological drugs that have been copied from the biological reference drug after the period of market protection had ended. They are comparable t ...
New drug: lasmiditan for migraine attacks
Two new drugs for the acute treatment of migraine attacks were authorised in 2022. They concern the ‘calcitonin gene-related peptide’ (CGRP) antagonist rimegepant, which was previously discussed in Ge-Bu, and the 5HT1F agonist lasmiditan. New age ...
